Hyperparathyroidism - Pipeline Insight, 2026

DelveInsight's, "Hyperparathyroidism - Pipeline Insight, 2026" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hyperparathyroidism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Hyperparathyroidism: Understanding

Hyperparathyroidism: Overview

Hyperparathyroidism is a condition in which the body produces excessive parathyroid hormone (PTH) from the four small parathyroid glands located behind the thyroid in the neck. This hormone plays a crucial role in regulating calcium and phosphorus levels, which are essential for proper nerve, muscle, and bone function. There are two main types: primary hyperparathyroidism, where one or more glands overproduce PTH leading to high blood calcium levels, and secondary hyperparathyroidism, which occurs when another condition such as kidney disease, intestinal disorders, or vitamin D deficiency causes low calcium levels, prompting the glands to increase hormone production.

Symptoms are often mild or unnoticed initially but can worsen over time and include frequent urination, excessive thirst, fatigue, weakness, bone and joint pain, abdominal discomfort, nausea, constipation, itchy skin, depression, and difficulty concentrating. In many cases, especially primary hyperparathyroidism, individuals may have no noticeable symptoms and the condition is often detected incidentally through blood tests showing elevated calcium levels.

PTH, produced by the chief cells of the parathyroid glands, regulates extracellular calcium homeostasis through feedback mechanisms mediated by the calcium-sensing receptor (CaSR). A decrease in serum ionized calcium reduces CaSR activity, which stimulates PTH secretion. PTH subsequently increases bone resorption, enhances distal tubular calcium reabsorption, and activates renal 1-a-hydroxylase, thereby promoting intestinal calcium absorption via 1,25-dihydroxyvitamin D. In primary hyperparathyroidism, clonal overactivity of parathyroid tissue elevates the set-point for calcium-mediated inhibition, resulting in persistent PTH secretion despite hypercalcemia. The typical biochemical profile includes elevated serum calcium, low or low-normal serum phosphate, and variable hypercalciuria due to increased filtered calcium load exceeding tubular reabsorption capacity.

The etiology of hyperparathyroidism, particularly primary hyperparathyroidism (PHPT), is driven by autonomous overproduction of PTH independent of normal calcium feedback control. This is caused by clonal proliferation and dysregulation of parathyroid tissue, most commonly a single adenoma (80-85% of cases), with less frequent causes including multigland hyperplasia or multiple adenomas (10-15%) and, rarely, carcinoma (<1%). A central mechanism involves impaired function or reduced expression of calcium-sensing receptors (CaSR), which disrupts normal feedback inhibition and allows persistent PTH secretion despite elevated calcium levels.

The diagnosis of hyperparathyroidism is primarily biochemical and established by the presence of persistent hypercalcemia alongside an inappropriately elevated or normal PTH level, reflecting loss of normal feedback regulation. Evaluation includes correction of serum calcium for albumin or direct measurement of ionized calcium, along with assessment of phosphorus (often low), renal function, and vitamin D status to exclude secondary causes. Management is centered on parathyroidectomy, the only definitive treatment, which offers high cure rates and improves bone, renal, and overall outcomes; it is recommended for all symptomatic patients and many asymptomatic individuals meeting specific clinical or biochemical criteria. For patients who are asymptomatic or unfit for surgery, medical management focuses on controlling hypercalcemia, preserving bone density, and monitoring complications through measures such as adequate calcium and vitamin D intake, use of calcimimetics like cinacalcet, and antiresorptive therapies.

"Hyperparathyroidism - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperparathyroidism pipeline landscape is provided which includes the disease overview and Hyperparathyroidism treatment guidelines. The assessment part of the report embraces, in depth Hyperparathyroidism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperparathyroidism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Hyperparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve Hyperparathyroidism.

Hyperparathyroidism Emerging Drugs Chapters

This segment of the Hyperparathyroidism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperparathyroidism Emerging Drugs

• SHR6508: Shanghai Hengrui Pharmaceutical Co., Ltd.

SHR6508 is a novel, small-molecule calcimimetic agent acting as a calcium-sensing receptor (CaSR) agonist developed by Shanghai Hengrui Pharmaceutical for the treatment of secondary hyperparathyroidism (SHPT). It works by activating CaSR on parathyroid gland cells, which suppresses the synthesis and release of parathyroid hormone (PTH), thereby reducing PTH, serum calcium, and phosphorus levels. This leads to reductions in circulating PTH levels as well as serum calcium and phosphorus concentrations. By directly targeting the underlying dysregulation of calcium homeostasis, SHR6508 aims to improve biochemical control while potentially offering better tolerability and dosing convenience compared to earlier calcimimetics. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Hyperparathyroidism.

Hyperparathyroidism: Therapeutic Assessment

This segment of the report provides insights about the different Hyperparathyroidism drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hyperparathyroidism
• There are approx. 3+ key companies which are developing the therapies for Hyperparathyroidism. The companies which have their Hyperparathyroidism drug candidates in the most advanced stage, i.e. Phase III include, Shanghai Hengrui Pharmaceutical Co., Ltd.
• Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hyperparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperparathyroidism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperparathyroidism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperparathyroidism drugs.

Hyperparathyroidism Report Insights

• Hyperparathyroidism Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hyperparathyroidism Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperparathyroidism drugs?
• How many Hyperparathyroidism drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperparathyroidism?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hyperparathyroidism therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperparathyroidism and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Shanghai Hengrui Pharmaceutical Co., Ltd.
• Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Key Products

• SHR6508
• MT1013